Duane Morris is pleased to announce that Kevin M. Nelson has joined the firm’s Intellectual Property Practice Group as a partner in its Chicago office. Nelson further strengthens Duane Morris’ IP practice, particularly in its growing generic pharmaceuticals and Hatch-Waxman practice. Duane Morris is one of the leading law firms representing generic and biogeneric companies in IP litigation, products liability and regulatory matters, and is committed to maintaining its active and growing practice in this area. Nelson joins Duane Morris from Locke Lord LLP.
Nelson focuses his practice on complex pharmaceutical patent litigation. For the past 12 years, he has represented generic drug companies in patent litigation brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Nelson has had substantial first-chair trial experience and has represented clients before the U.S. Court of Appeals for the Federal Circuit. Nelson has also represented clients before the U.S. Food and Drug Administration (FDA) in regulatory matters and in opposing citizen petitions. In addition, he has experience advising clients regarding biosimilars applications and litigation. Nelson also has experience in copyright and trademark litigation, trademark oppositions, antitrust litigation and client counseling on electronic discovery readiness.
Nelson frequently writes on topics, including the impact of FDA guidances and other patent litigation matters.
He earned his J.D. in 2001 from DePaul University College of Law and graduated with a B.A. in Political Science in 1998 from Indiana University.
